Subscribe To
Uvax Bio Announces Publication of Results from Preclinical Studies of HIV Vaccine Candidates
Uvax Bio-owned vaccines demonstrated significant improvement in immune response compared with current vaccine strategies Phase 1 clinical trial sponsored by National Institutes of Health expected to commence in 2024 NEWARK, Del., April 26, 2023 (GLOBE NEWSWIRE) — Uvax Bio, LLC, a privately held, preclinical-stage vaccine company, today announced that its HIV vaccine candidates have shown […] The post Uvax Bio Announces Publication of Results from Preclinical Studies of HIV Vaccine Candidates app...
Read More
Posted: Apr 26 2023, 11:30
Author Name: forextv
Views: 091953